文献速递类风湿关节炎脊柱关节炎

强制从原研依那西普换用生物类似药SB4对医疗资源使用与费用的影响:丹麦注册研究

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.
PubMed 文献 · RMD Open · 2019-08-12

该研究基于丹麦全国注册数据,纳入1620例从原研依那西普强制换用生物类似药SB4的炎症性关节炎患者,比较换药前后1年的医疗资源使用与费用。结果显示换药后门诊服务使用(8%)与费用(7%)增加,住院费用(55%)与药物费用(5%)下降,总体医疗资源使用与费用无显著变化。

要点

  • 强制换用SB4后门诊服务使用与费用小幅增加,住院与药物费用下降。
  • 总体医疗资源使用与费用在换药前后无显著变化。
  • 依那西普治疗时间较长的患者换药后医疗资源使用与费用增加。

核心结论

  • 从原研依那西普强制换用生物类似药SB4后,整体医疗服务使用与费用未见明显变化。

研究设计与样本

  • 观察性队列研究,纳入丹麦全国DANBIO注册系统中1620例从原研依那西普换用SB4的成人炎症性风湿病患者(平均年龄55岁,SD 14.7,40%男性)。

主要发现

  • 换药前后费用主要由门诊就诊驱动(分别占全部费用的67%和72%)。
  • 换药后门诊服务使用增加8%、费用增加7%,住院费用下降55%、药物费用下降5%。
  • 依那西普治疗时间较长的患者换药后医疗资源使用与费用增加,性别与合并症无影响,较高年龄与住院服务费用增加相关。

临床怎么用

  • 强制从原研依那西普换用生物类似药SB4在常规诊疗中未导致整体医疗资源使用与费用的明显增加。

局限性

  • 模型未纳入依那西普与SB4的药物费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In year 2016, Danish national guidelines included a mandatory switch of patients with inflammatory rheumatic diseases treated with originator etanercept (ETA) to biosimilar SB4 in routine care. We aimed to explore if switching lead to increased healthcare utilisation and costs. METHODS: Observational cohort study. Adult patients who switched from ETA to SB4 were identified in the Danish nationwide DANBIO registry. In the National Patient Registry, we identified health utilisation (hospital admissions/hospital days/outpatient visits/prescription medication use) and comorbidities. Estimation of health utilisation included average use and costs 1 year before/after switch, changes after the switch, and whether patient characteristics affected changes. Analyses were by adjusted two-step gamma distributed regression models, and for changes over time a generalized estimation equations (GEE) model was applied. Impact of comorbidities was explored as interaction terms in the model. Medication costs of ETA and SB4 were not included in model. RESULTS: 1620 patients were included (mean age 55 years (SD 14.7), 40% male). Costs before and after switching were mainly driven by outpatient visits (67%/72% of all costs). Monthly fluctuations of costs were similar before/after switch. After switching, use (8%) and costs (7%) of outpatient services increased, whereas costs of admissions (55%) and medication (5%) decreased. Patients with longer ETA treatment duration had an increase in use and costs of healthcare resources, whereas gender and comorbidities had no impact. Higher age was associated with an increase in costs of inpatient services. CONCLUSION: We demonstrated no obvious changes in overall use and costs of healthcare services following switch from originator to biosimilar etanercept.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Glintborg B, Ibsen R, Bilbo REQ, et al. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open. 2019. PMID: 31452931. doi:10.1136/rmdopen-2019-001016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。